Human Milk Oligosaccharides Market, By Application (Infant Formula, Dietary Supplements, and Functional Food and Beverage), By Type (2’FL, 3’FL, 3’SL, 6’SL, LNT, and LNnT), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jul 2024

Code : CMI5064

Pages :120

Formats :

Excel and PDF

Industry : Food and Beverages

Key Developments

In 2022, Kyowa Hakko Bio Co. Ltd, a subsidiary of Kirin Holdings Company, completed the construction of a production facility for human milk oligosaccharides (HMOs) at its Thai subsidiary, Thai Kyowa Biotechnologies Co., Ltd.
In 2022, FrieslandCampina's 2'-fucosyllactose, branded as Aequival, received approval from authorities in Australia and New Zealand for use in infant milk formula. The company is also set to expand its human milk oligosaccharide (HMO) portfolio with the upcoming launch of Lacto-N-tetraose (LNT), 3-fucosyllactose (3-FL), 3'-Sialyllactose (3'-SL), and 6-Sialyllactose (6-SL). These HMOs play a crucial role in establishing the infant's gut microbiota and metabolism, while some variants help prevent pathogens from adhering to intestinal cells, thereby reducing the risk of infection.
In 2021, Chr Hansen signed an agreement with industrial biotechnology company, Jennewein Biotechnologie, to acquire its complete stake.
In 2021, BASF SE announced that PREBILAC, BASF’s brand of 2’-FL, had received approval from the Australia’s Therapeutic Goods Administration (TGA), making it the first and only 2’-FL ingredients to receive TGA approval as a prebiotic ingredient